Evaluation of Haemate HS for the treatment of severe intraoperative hemorrhage during aortic-valve replacement in patients with aortic-valve stenosis

Submission date	Recruitment status	Prospectively registered
07/12/2007	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
08/02/2008	Completed	Results
Last Edited	Condition category	Individual participant data
08/02/2008	Circulatory System	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Rainer Zotz

Contact details

Department of Hemostasis and Transfusion Medicine Heinrich Heine University Medical Center Moorenstrasse 5 Duesseldorf Germany D-40225 +49(0)211 8117474 Nicola.Moeller@med.uni-duesseldorf.de

Additional identifiers

Protocol serial number BI8021_5101

Study information

Scientific Title

Acronym

HAVAS-Study

Study objectives

Evaluation of the efficacy and safety of Haemate HS in this clinical setting

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved by the Ethics Committee of the Heinrich Heine University Medical Center (Duesseldorf, Germany) on 25 April 2007. First amendment approved on 28 November 2007.

Study design

Two-arm, randomised, double-blind controlled clinical study.

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Severe intraoperative hemorrhage during aortic-valve replacement

Interventions

Intervention group: Intraoperative infusion Haemate HS 500/1000 IU (vWF/F VIII:C concentrate), time of infusion according to inclusion criteria.

Control group: Intravenous infusion of 0.9% NaCl solution (100 ml)

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Haemate HS (intraoperative infusion)

Primary outcome(s)

Intra- and postoperative transfusion requirements according to defined transfusion thresholds.

Key secondary outcome(s))

- 1. Requirement of rethoracotomy, assessed during patients stay at the intensive care unit
- 2. Surgeons' subjective rating of therapeutic efficacy after application of Haemate HS or placebo (classification of bleeding after therapy as "better", "equal" or "worse")
- 3. Survival (perioperative mortality, mortality during hospital stay, mortality within a 90 day

period following surgery)

- 4. Duration of treatment on intensive care ward
- 5. Adverse events and therapy-related side effects, assessed within the first 10 days after surgery. A second assessment is carried out after 3 month (at day 90)

Completion date

31/12/2009

Eligibility

Key inclusion criteria

- 1. Patients with isolated valvular aortic stenosis or combined aortic-valve defect with prevailing stenosis (mean transvalvular gradient >50 mmHg) with severe bleeding during aortic-valve replacement
- 2. Age >18 years.
- 3. Written informed consent.
- 4. All patients that fulfill at least one of the following criteria 15 minutes after the end of extracorporal circulation and application of protamine:
- 4.1. Excessive bleeding without surgical explanation according to the surgeons' impression (Classification of bleeding as "normal", "moderate" or "excessive" by the surgeon. Classification as "excessive" bleeding leads to recruitment to the study).
- 4.2. Drainage volume >40 ml in 5 minutes following application of protamine and thorax closure.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

- 1. Participation in other interventional studies that potentially impair the interpretation of results
- 2. History suggestive for inherited or acquired bleeding disorder
- 3. Written informed consent not to be obtained
- 4. Active endocarditis
- 5. Concomitant coronary heart disease
- 6. Agents impairing platelet function at the time of surgery
- 7. Pregnancy
- 8. Known or suspected intolerance against Haemate HS
- 9. Previous thromboembolic complications
- 10. Known hepatitis B, hepatitis C or HIV infection

- 11. Known or suspected intolerance against standard medication (e.g., heparin)
- 12. Emergency surgery within the last 7 days
- 13. Previous chemotherapy

Date of first enrolment

19/10/2007

Date of final enrolment

31/12/2009

Locations

Countries of recruitment

Germany

Study participating centre

Department of Hemostasis and Transfusion Medicine

Duesseldorf Germany D-40225

Sponsor information

Organisation

Heinrich Heine University Duesseldorf (Germany)

ROR

https://ror.org/024z2rq82

Funder(s)

Funder type

Industry

Funder Name

CSL Behring GmbH (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet Participant information sheet 11/11/2025 No Yes